NCT02502266 2026-03-05Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian CancerNational Cancer Institute (NCI)Phase 2/3 Active not recruiting582 enrolled 21 charts